|
|
|
|
Hear from some of the experts who were instrumental in developing the Accelerated mAb development program and who work with biotech companies on a daily basis to accelerate their timelines toward the production of GMP drug substances. Reduce development timelines for IgG1 and IgG4 mAbs using this established, phase-appropriate process.
|
|
|
|
|
An emerging biotech company sought help developing a formulation for a mAb. The company lacked in-house development expertise and wanted a partner capable of delivering an optimized formulation of buffers and excipients within an aggressive timeline and budget. Explore how we delivered an optimized formulation in three months.
|
|
|
|
|
Making the right decisions at the right time is crucial to the success of a biopharma executive. In this guidebook, experts share key considerations to help biopharmaceutical companies successfully advance a molecule from laboratory to clinic as quickly as possible without sacrificing product quality, process efficiency, or patient safety.
|
|
|
|
|
|
Accelerated mAb Development Program
|
Today’s biotech landscape is highly competitive. Expediting progress from cell line development to the production of GMP drug substances for Phase 1 and Phase 2 clinical trials is essential for success. Discover how, with the Accelerated mAb Development Program, biotech companies of all sizes can reduce the time and cost to clinic with confidence.
|
|
• Request Information
|
|
|
|
|
|
|
|
